Sodium-glucose cotransporter-2 inhibitors protect tissues via cellular and mitochondrial pathways: Experimental and clinical evidence

doi:10.5493/wjem.v14.i2.91519

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1605)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

HTML

1121

Figures (1-1)

118

Tables (1-1)

148

Sum=1432

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=109

Jun 20, 2024 (publication date) through Nov 8, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315x

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Exp Med. Jun 20, 2024; 14(2): 91519
Published online Jun 20, 2024. doi: 10.5493/wjem.v14.i2.91519

Sodium-glucose cotransporter-2 inhibitors protect tissues via cellular and mitochondrial pathways: Experimental and clinical evidence

Raúl Lelio Sanz, Sebastián García Menéndez, Felipe Inserra, Leon Ferder, Walter Manucha

Raúl Lelio Sanz, Sebastián García Menéndez, Walter Manucha, Department of Pathology, Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza 5500, Argentina

Sebastián García Menéndez, Walter Manucha, Department of Pharmacology, Instituto de Medicina y Biología Experimental de Cuyo, Centro Científico Tecnológico, Mendoza 5500, Argentina

Felipe Inserra, Department of Nephrology, Universidad de Maimónides, Ciudad Autónoma de Buenos Aires C1405, Argentina

Leon Ferder, Department of Cardiology, Universidad de Maimónides, Ciudad Autónoma de Buenos Aires C1405, Argentina

Author contributions: Sanz RL, García Menéndez S, Inserra F, Ferder L, Manucha W did substantial contributions to conception and design of the manuscript, made critical revisions related to the important intellectual content of the manuscript, and provided final approval of the version of the article to be published.

Conflict-of-interest statement: The authors declare that there are no conflicts of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Walter Manucha, PhD, Adjunct Professor, Department of Pathology, Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Campus Universitario Uncuyo, Mendoza 5500, Argentina. wmanucha@fcm.uncu.edu.ar

Received: December 29, 2023
Revised: February 7, 2024
Accepted: April 11, 2024
Published online: June 20, 2024
Processing time: 172 Days and 14.1 Hours

Core Tip

Core Tip: Sodium-glucose cotransporter-2 inhibitors, diabetes drugs, unlock tissue protection via diverse pathways. They boost mitochondrial efficiency, curb oxidative stress and inflammation, and enhance autophagy. Clinical trials show cardiovascular benefits, suggesting immense potential beyond diabetes and even towards anti-aging therapy.